Table 2.

Prognostic evidence base of stress cardiovascular magnetic resonance

Investigators	n	Stress agent	Study performance	Follow-up	End point
Dall’Armellina et al. [1]	200	Dobutamine	WMA	5 y	MI/mortality/CHF
Wallace et al. [29]	266	Dobutamine	WMA	6.2 y	MI/mortality
Walsh et al. [30]	157	Dobutamine	WMA	5.5 y	MI/mortality/CHF
Charoenpanichkit et al. [31]	62	Dobutamine	WMA	6 y	MI/mortality
Korosoglou et al. [32]	1,493	Dobutamine	Perfusion and WMA	2 y	MI/mortality/revascularization
Bodi et al. [40]	601	Dipyridamole	Perfusion and WMA	553 d	MACE/mortality
Doesch et al. [41]	81	Adenosine	Perfusion	30 mo	MI/mortality/revascularization
Lerakis et al. [35]	103	Adenosine	Perfusion	277 d	MACE/mortality
Steel et al. [42]	254	Adenosine	Perfusion and LGE	30 mo	MACE/mortality
Husser et al. [43]	192	Adenosine	Perfusion and LGE	655 d	MACE/mortality

CHF congestive heart failure; LGE late gadolinium enhancement; MACE major adverse cardiac events; MI myocardial infarction; WMA wall motion abnormality